Please select the option that best describes you:

Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?  

Patient progressed on osimertinib but on resequencing still had EGFR L858R mutation and developed ALK fusion. If so, what agent and what dosing in combination with osimertinib?